What will Ophthalmic Gene Therapy and Stem Cell treatment cost and how will we and the healthcare system pay for it?
With the likelihood of a gene therapy and/or a stem cell treatment for retinal diseases to be approved for marketing within the next two to three years, it is time for the ophthalmic community – the suppliers, practitioners, patients and payers – to start thinking about how much these regenerative medicine treatments are likely to cost, and how patients and the healthcare system will pay for them..
In The Economics of Gene Therapy, I propose a pricing model for Regenerative Medicine in Ophthalmology, based on the population of patients to be treated, and suggest that an annuity program model, based on performance and duration of efficacy, could be used to pay for it.
Let the dialogue begin.
To read all about it, please follow this link:
We thank Irv Arons for his information, help and knowledge.